ISSN 1004-4140
CN 11-3017/P

不同病程的COVID-19临床与CT影像特征比较分析

张明霞, 李玲, 孙莹, 郭佳, 杜常月, 李兴鹏, 张妍, 郝琪, 段淑红, 刘晓燕, 孙磊, 霍萌, 张春燕, 王仁贵

张明霞, 李玲, 孙莹, 等. 不同病程的COVID-19临床与CT影像特征比较分析[J]. CT理论与应用研究, 2023, 32(3): 380-386. DOI: 10.15953/j.ctta.2023.021.
引用本文: 张明霞, 李玲, 孙莹, 等. 不同病程的COVID-19临床与CT影像特征比较分析[J]. CT理论与应用研究, 2023, 32(3): 380-386. DOI: 10.15953/j.ctta.2023.021.
ZHANG M X, LI L, SUN Y, et al. Comparative Analysis of Clinical and Computed Tomography Imaging Features of COVID-19 with Different Disease Courses[J]. CT Theory and Applications, 2023, 32(3): 380-386. DOI: 10.15953/j.ctta.2023.021. (in Chinese).
Citation: ZHANG M X, LI L, SUN Y, et al. Comparative Analysis of Clinical and Computed Tomography Imaging Features of COVID-19 with Different Disease Courses[J]. CT Theory and Applications, 2023, 32(3): 380-386. DOI: 10.15953/j.ctta.2023.021. (in Chinese).

不同病程的COVID-19临床与CT影像特征比较分析

详细信息
    作者简介:

    张明霞: 女,首都医科大学附属北京世纪坛医院放射科主治医师,主要从事胸部疾病影像诊断学研究,E-mail:sjtzhangmingxia@qq.com

    通讯作者:

    张春燕: 女,医学博士,首都医科大学附属北京世纪坛医院放射中心副主任医师,主要从事呼吸系统和淋巴影像学临床医疗、教学及科研工作,E-mail:linyajun20002004@163.com

    王仁贵: 男,医学博士,首都医科大学附属北京世纪坛医院放射中心主任、主任医师、教授、博士生导师,主要从事淋巴影像学、呼吸肿瘤和肺部弥漫性疾病的影像学研究,E-mail:wangrg@bjsjth.cn

  • 中图分类号: R  814;R  563.1

Comparative Analysis of Clinical and Computed Tomography Imaging Features of COVID-19 with Different Disease Courses

  • 摘要: 目的:比较分析不同病程的新型冠状病毒感染(COVID-19)患者的临床与胸部CT影像特征。方法:回顾性分析2022年12月至2023年1月期间于首都医科大学附属北京世纪坛医院发热门诊收治的161例COVID-19确诊且胸部CT显示肺部感染阳性的病例,按CT检查时发病时间不同分为两组:<10 d及≥10 d,对两组病例的临床表现和胸部CT影像学特征进行统计学分析。结果:<10 d组共92例(57.1%)、≥10 d组共69例(42.9%),两组病例临床症状比较显示,两组间咽痛和肌痛的比例存在统计学差异;实验室指标显示,<10 d组的C反应蛋白更高、淋巴细胞计数更低,其差异存在统计学意义;在CT影像特征方面,<10 d组患者存在血管周、混合分布、大片、空气支气管征的比例更高,≥10 d组患者存在边界不规则、病灶内索条、反晕征、胸膜尾征、胸膜下线、胸膜下栅栏的比例更高,差异有统计学意义。结论:COVID-19的临床症状、实验室指标、CT影像特征随病程不同发生变化,探索其中的规律可以帮助临床医生更好地诊断和治疗COVID-19肺部感染。
    Abstract: Objective: To compare and analyze the clinical and chest computed tomography (CT) imaging features of COVID-19 patients with different disease courses. Methods: A retrospective analysis was performed for 161 cases with confirmed COVID-19 and positive chest CT lung infections from December 2022 to January 2023 at the fever clinic of Beijing Shijitan Hospital affiliated with Capital Medical University. The patients were divided into two groups based on the time of CT examination: <10 days and ≥10 days. We statistically analyzed the clinical manifestations and chest CT imaging characteristics of the two groups. Results: Of the 161 cases, 92 cases (57.1%) were in the <10-day group, and 69 cases (42.9%) were in the ≥10-day group. The clinical symptoms of the two groups showed that there was a statistical difference in the proportion of sore throat and myalgia between the two groups. Laboratory indicators showed that the C-reactive protein and lymphocyte count were significantly higher in the <10-day group. In terms of CT imaging features, the proportion of patients with perivascular, mixed distribution, large area, and air bronchogram was higher in the patients from the <10-day group, while the patients in the ≥10-day group had a significantly higher proportion of irregular boundaries, intralesional cord, reversed halo sign, pleural tail sign, subpleural line, and subpleural palisade. Conclusion: The clinical symptoms, laboratory indexes, and CT imaging features of COVID-19 pulmonary infection differed depending on the disease course, and exploring these differences can help clinicians diagnose and treat COVID-19 lung infections more effectively.
  • 图  1   COVID-19肺部感染的相关影像学征象

    Figure  1.   Imaging signs associated with COVID-19 lung infection

    表  1   不同病程患者组临床症状占比情况

    Table  1   Proportion of clinical symptoms in different disease course groups

    临床指标组别统计检验
    <10 d≥10 d$Z/\chi^{2}$P
       年龄($M(Q_1,Q_3)$) 69(59,82) 70(59,79)-0.3280.743
       性别(男,例(%))52(56.5)39(56.5)0.0001.000
       发热/(例(%)) 92(100.0) 69(100.0)
       憋气/(例(%))13(14.1)14(20.3)1.0720.301
       咳嗽/(例(%))45(48.9)37(53.6)0.1120.738
       咳痰/(例(%))84(91.3)64(92.8)0.3500.554
       咽痛/(例(%))43(46.7)19(27.5)6.1400.013
       肌痛/(例(%))3(3.3) 9(13.0)5.4700.019
    下载: 导出CSV

    表  2   不同病程患者组实验室指标对比情况

    Table  2   Comparison of laboratory indicators in different disease course groups

    实验室指标($M(Q_1,Q_3)$)组别统计检验
    <10 d≥10 dZP
      C反应蛋白/(mg/L) 32.71(11.52,67.57)15.70(2.88,50.93)-2.7610.006
      白细胞/(×109/L)6.23(4.82,7.74)6.99(5.10,8.29)-1.5700.116
      淋巴细胞/(×109/L)1.31(0.99,1.69)1.78(1.03,2.41)-2.9790.003
      单核细胞/(×109/L)0.35(0.44,0.61)0.47(0.37,0.59)-0.297-0.766
      中性粒细胞/(×109/L)4.09(3.01,5.89)4.22(3.19,5.90)-0.4780.632
    下载: 导出CSV

    表  3   不同病程患者组病灶各类影像征象占比情况

    Table  3   Proportion of various imaging signs in the lesions of patients with different disease course

    影像指标组别统计检验
    <10 d(92例)≥10 d(69例)$\chi^{2} $P
    分布特征/(例(%))     周围88(95.7)68(98.6)1.1010.294
      胸膜下67(72.8)49(71.0)0.0640.800
      胸膜内85(92.4)66(95.7)0.7200.396
      中央74(80.4)45(65.2)4.7350.030
      血管周74(80.4)43(62.3)6.5150.011
      血管外10(10.9) 8(11.6)0.0210.885
      混合71(77.2)42(60.9)5.0090.025
    分布优势/(例(%))     上肺为主10(10.9)6(8.7)0.2080.648
      下肺为主41(44.6)43(62.3)3.8460.050
    病变形态/(例(%))     斑片状81(88.0)56(81.2)1.4730.225
      大片状56(60.9)25(36.2)9.5740.002
      束带状39(42.4)34(49.3)0.7540.385
    实变相关征象/(例(%))42(45.7)29(42.0)0.2100.647
      铺路石征56(60.9)35(50.7)1.6511.199
      空气支气管征69(75.0)32(46.4)13.817 0.000
      空泡征52(56.5)38(55.9)0.0060.936
    机化纤维化征象/(例(%))  蜂窝9(9.8) 9(13.0)9.4140.516
      边界不规则40(43.5)44(63.8)6.5050.011
      病灶内索条22(23.9)37(53.6)14.991 0.000
      纤维索条61(66.3)51(73.9)1.0780.299
      牵拉支扩50(54.3)45(65.2)1.9260.165
      反晕征30(32.6)37(53.6)7.1660.007
      煎蛋征46(50.0)42(60.9)1.8800.170
      胸膜尾征38(41.3)44(63.8)7.9610.005
      胸膜下线21(22.8)34(49.3)12.264 0.000
      胸膜下栅栏7(7.6)26(37.7)21.881 0.000
    胸膜病变/(例(%))     胸膜增厚68(73.9)56(81.2)1.1700.279
      叶间裂增厚14(15.2)17(24.6)2.2510.134
      胸腔积液3(3.3) 3(4.3)0.1300.719
    下载: 导出CSV
  • [1]

    WHO Coronavirus (COVID-19) Dashboard. Worle health organization[EB/OL]. [2023-02]. https://covid19.who.int.

    [2]

    YE Z, ZHANG Y, WANG Y, et al. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): A pictorial review[J]. European Radiology, 2020, 30(8): 4381−4389.

    [3]

    SINGANAYAGAM A, PATEL M, CHARLETT A, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020[J]. European Surveillance, 2020, 25(32): 2001483.

    [4] 李华侨, 陈建新, 黄云华, 等. 新型冠状病毒肺炎患者临床及CT影像特点分析[J]. 国际病毒学杂志, 2022,29(1): 1−4. DOI: 10.3760/cma.j.issn.1673-4092.2022.01.001.

    LI H J, CHEN J X, HUANG Y H, et al. Ananalysis on clinical and CT imaging features of COVID-19 patients[J]. International Journal of Virology, 2022, 29(1): 1−4. DOI: 10.3760/cma.j.issn.1673-4092.2022.01.001. (in Chinese).

    [5]

    SMILOWITZ N R, KUNICHOFF D, GARSHICK M, et al. C-reactive protein and clinical outcomes in patients with COVID-19[J]. European Heart Journal, 2021, 42(23): 2270−2279. DOI: 10.1093/eurheartj/ehaa1103.

    [6]

    VOLANAKIS J E. Human C-reactive protein: Expression, structure, and function[J]. Molecular Immunology, 2001, 38(2/3): 189−197.

    [7]

    LENTNER J, ADAMS T, KNUTSON V, et al. C-reactive protein levels associated with COVID-19 outcomes in the United States[J]. Journal of Osteopathic Medicine, 2021, 121(12): 869−873. doi: 10.1515/jom-2021-0103

    [8]

    PONTI G, MACCAFERRI M, RUINI C, et al. Biomarkers associated with COVID-19 disease progression[J]. Critical Reviews in Clinical Laboratory Sciences, 2020, 57(6): 389−399. doi: 10.1080/10408363.2020.1770685

    [9] 陈婉玲, 王伟峰, 李文涛, 等. COVID-19患者外周血T淋巴细胞计数动态变化研究[J]. 中华微生物学和免疫学杂志, 2020,40(7): 495−498. DOI: 10.3760/cma.j.cn112309-20200301-00089.

    CHEN W L, WANG W F, LI W T, et al. Dynamic changes of peripheral blood T lymphocytes in COVID-19 patients[J]. Chinese Journal of Microbiology and Immunology, 2020, 40(7): 495−498. DOI: 10.3760/cma.j.cn112309-20200301-00089. (in Chinese).

    [10]

    LIU C, CAI J, ZHANG M, et al. Clinical characteristics and CT imaging features of COVID-19 on admission: A retrospective study[J]. Current Medical Imaging, 2021, 17(11): 1324−1329.

    [11]

    XU X, CHEN P, WANG J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[J]. Science China Life Sciences, 2020, 63(3): 457−460. doi: 10.1007/s11427-020-1637-5

    [12]

    BATAH S S, FABRO A T. Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians[J]. Respiratory Medicine, 2021, 176: 106239. doi: 10.1016/j.rmed.2020.106239

    [13]

    YAO X H, LUO T, SHI Y, et al. A cohort autopsy study defines COVID-19 systemic pathogenesis[J]. Cell Research., 2021, 31(8): 836−846. doi: 10.1038/s41422-021-00523-8

    [14]

    HANSELL D M, BANKIER A A, Mac MAHON H, et al. Fleischner Society: Glossary of terms for thoracic imaging[J]. Radiology, 2008, 246(3): 697−722. doi: 10.1148/radiol.2462070712

    [15]

    HUANG P, LIU T, HUANG L, et al. Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion[J]. Radiology, 2020, 295(1): 22−23. doi: 10.1148/radiol.2020200330

    [16]

    KONG W, AGARWAL P P. Chest imaging appearance of COVID-19 infection[J]. Radiology Cardiothoracic Imaging, 2020, 2(1): e200028. doi: 10.1148/ryct.2020200028

    [17]

    PAN Y, GUAN H, ZHOU S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): A study of 63 patients in Wuhan, China[J]. European Radiology, 2020, 30(6): 3306−3309. doi: 10.1007/s00330-020-06731-x

    [18]

    PAN F, YE T, SUN P, et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19)[J]. Radiology, 2020, 295(3): 715−721. doi: 10.1148/radiol.2020200370

图(1)  /  表(3)
计量
  • 文章访问数:  160
  • HTML全文浏览量:  64
  • PDF下载量:  153
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-02-13
  • 修回日期:  2023-03-07
  • 录用日期:  2023-03-08
  • 网络出版日期:  2023-04-22
  • 发布日期:  2023-05-30

目录

    /

    返回文章
    返回
    x 关闭 永久关闭